Alto Neuroscience, Inc. Share Price

Equities

ANRO

US02157Q1094

Biotechnology & Medical Research

Market Closed - Nyse 21:00:01 22/04/2024 BST 5-day change 1st Jan Change
13.64 USD +5.25% Intraday chart for Alto Neuroscience, Inc. -3.60% 0.00%
Sales 2024 * - Sales 2025 * - Capitalization 366M 29.66B
Net income 2024 * -56M -4.53B Net income 2025 * -80M -6.48B EV / Sales 2024 * -
Net cash position 2024 * 350M 28.36B Net cash position 2025 * 277M 22.39B EV / Sales 2025 * -
P/E ratio 2024 *
-6.91 x
P/E ratio 2025 *
-5.37 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.89%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.25%
1 week-3.60%
Current month-11.14%
1 month-14.59%
More quotes
1 week
12.78
Extreme 12.7798
13.81
1 month
12.78
Extreme 12.7798
18.35
Current year
12.78
Extreme 12.7798
24.00
1 year
12.78
Extreme 12.7798
24.00
3 years
12.78
Extreme 12.7798
24.00
5 years
12.78
Extreme 12.7798
24.00
10 years
12.78
Extreme 12.7798
24.00
More quotes
Date Price Change Volume
22/04/24 13.64 +5.25% 82,863
19/04/24 12.96 -4.00% 235,763
18/04/24 13.5 +0.15% 79,670
17/04/24 13.48 -0.66% 155,358
16/04/24 13.57 -4.10% 84,141

Delayed Quote Nyse, April 22, 2024 at 09:00 pm

More quotes
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and effective treatment options. Through insights derived from the Company’s scalable and proprietary Precision Psychiatry Platform, which applies rigorous data science and robust analytics to data gathered by neurocognitive assessments, electroencephalography, and wearable devices, the Company aims to discover brain-based biomarkers to better identify which patients are more likely to respond to its novel product candidates. Its pipeline consists of five clinical-stage assets, such as ALTO-100, ALTO-202, ALTO-300, ALTO-101, and ALTO-203, which target depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers. Its pipeline also includes novel drug candidates in depression, post-traumatic stress disorder (PTSD), and other mental health conditions.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.64 USD
Average target price
33.31 USD
Spread / Average Target
+144.23%
Consensus